Insmed Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $606.4M | $363.7M | $305.2M | $245.4M | $188.5M | $164.4M | $136.5M |
| Cost of Revenue | — | $122.9M | $85.7M | $65.6M | $55.1M | $44.2M | $39.9M | $24.2M |
| Gross Profit | — | $483.5M | $278.0M | $239.6M | $190.2M | $144.3M | $124.5M | $112.3M |
| Gross Margin | — | 79.7% | 76.4% | 78.5% | 77.5% | 76.6% | 75.7% | 82.3% |
| Operating Expenses | ||||||||
| Research & Development | — | $771.1M | $598.4M | $571.0M | $397.5M | $272.7M | $181.2M | $131.7M |
| SG&A Expense | — | $701.2M | $461.1M | $344.5M | $265.8M | $234.3M | $203.6M | $210.8M |
| Operating Income | — | $-1.25B | $-878.3M | $-709.6M | $-457.3M | $-375.1M | $-265.2M | $-235.2M |
| Operating Margin | — | -205.6% | -241.5% | -232.5% | -186.4% | -199.0% | -161.3% | -172.4% |
| Interest Expense | — | $83.8M | $84.9M | $81.7M | $26.4M | $40.5M | $29.6M | $27.7M |
| Pretax Income | — | $-1.27B | $-910.1M | $-747.0M | $-480.2M | $-436.4M | $-292.7M | $-253.6M |
| Income Tax Expense | — | $5.0M | $3.7M | $2.6M | $1.4M | $-1.8M | $1.4M | $777.0K |
| Net Income | — | $-1.28B | $-913.8M | $-749.6M | $-481.5M | $-434.7M | $-294.1M | $-254.3M |
| Net Margin | — | -210.5% | -251.2% | -245.6% | -196.3% | -230.6% | -178.9% | -186.4% |
| EPS (Basic) | — | $-6.42 | $-5.57 | $-5.34 | $-3.91 | $-3.88 | $-3.01 | $-3.01 |
| EPS (Diluted) | — | $-6.42 | $-5.57 | $-5.34 | $-3.91 | $-3.88 | $-3.01 | $-3.01 |
| Shares Outstanding (Basic) | 215.6M | 199.0M | 164.0M | 140.4M | 123.0M | 112.1M | 97.6M | 84.6M |
| Shares Outstanding (Diluted) | 215.6M | 199.0M | 164.0M | 140.4M | 123.0M | 112.1M | 97.6M | 84.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |